GlobalData R&A lead says “virtual clinical trials are here to stay”
Data showing the sharp rise in virtual clinical trials has been detailed to delegates at the CTS Copenhagen conference explaining how virtual trials have quadrupled since 2019.
26 October 2023
26 October 2023
Data showing the sharp rise in virtual clinical trials has been detailed to delegates at the CTS Copenhagen conference explaining how virtual trials have quadrupled since 2019.
GSK plans to submit the data to regulatory agencies to support label expansion for Arexvy in the younger adult patient population in 2024.
MK-1942 was in Phase II trials for the treatment of Alzheimer’s disease and major depressive disorder.
Illumina proceeded with its re-acquisition of Grail despite the concerns of regulators, irking them and inviting Icahn's lawsuit.
The neuromodulation device delivers proprietary gamma frequency light and sound stimulation for the treatment of Alzheimer’s disease.
The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport.
The US company is developing its two devices for a global TAVR market expected to reach $18.8bn by 2033.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.